The short answer
Kava should be reviewed before use with hydromorphone because of possible added sedation. Guidance advises against combining kava with sedating substances, although the exact pair’s risk is unmeasured.
What this answer covers
Piper methysticum beverages and extracts; preparation differences matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- hydromorphone
Supplement guidance advises caution
Federal guidance advises against combining kava with sedatives. This supports a conditional precaution alongside hydromorphone, not a measured combination risk.
The opioid risk is established
Hydromorphone can cause sedation and dangerous respiratory depression. Its label warns that other CNS depressants can add to these effects, especially with other sedating medicines or alcohol.
An efficacy null does not prove safety
A trial found no primary anxiety or insomnia benefit from the tested kava or valerian preparations over placebo. It did not test hydromorphone, and a null symptom benefit does not exclude drowsiness.
Review the combination before adding it
Discuss the actual supplement with the prescriber and avoid driving when impaired. Slow or difficult breathing or being unusually hard to wake requires emergency help. Do not self-adjust hydromorphone or rely on a short supplement gap.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-sedation precaution from exact hydromorphone label plus supplement guidance/independent effects; no pair incidence or proven respiratory-depression magnitude.
- Exact scope
- Piper methysticum beverages and extracts; preparation differences matter. with Hydromorphone RxCUI3423 IN; HCl oral immediate-release, extended-release and injected products distinguished.
- Medication form and route
- oral medication; intravenous medication; intramuscular medication; subcutaneous medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed hydromorphone
Opioid respiratory depression and additive CNS-depressant risk; general serotonergic-drug warning. Constipation can be severe. Hydromorphone is extensively glucuronidated.
How this applies: Exact hydromorphone RxCUI 3423 IN, with stated salt/formulation/route bridge.
No supplement-specific incidence. Oral, injected and extended-release products differ; oral cannabinoid experiments cannot establish every route or formulation.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed hydromorphone
Opioid respiratory depression and additive CNS-depressant risk; general serotonergic-drug warning. Constipation can be severe. Hydromorphone is extensively glucuronidated.
How this applies: Exact hydromorphone RxCUI 3423 IN, with stated salt/formulation/route bridge.
No supplement-specific incidence. Oral, injected and extended-release products differ; oral cannabinoid experiments cannot establish every route or formulation.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed hydromorphone
Opioid respiratory depression and additive CNS-depressant risk; general serotonergic-drug warning. Constipation can be severe. Hydromorphone is extensively glucuronidated.
How this applies: Exact hydromorphone RxCUI 3423 IN, with stated salt/formulation/route bridge.
No supplement-specific incidence. Oral, injected and extended-release products differ; oral cannabinoid experiments cannot establish every route or formulation.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Original source interpreted for hydromorphone only within the stated preparation and endpoint limits.
Not a direct hydromorphone combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Efficacy null is not proof of no sedation. No hydromorphone; exact preparation not every root or kava product.
Efficacy null is not proof of no sedation. No hydromorphone; exact preparation not every root or kava product.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact hydromorphone article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 1c9b7672b2df4429
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.